Dravet syndrome
key facts

Inspired by **patients.**
Driven by **science.**

Dravet Syndrome is a rare and severe form of epilepsy[1,2]

A lifelong condition with significant impact on quality of life (QoL) for patients and families[3–5]

Doesn't respond well to treatment (treatment-resistant)[1,2]

Can affect development[1,2]

Usually starts in childhood[1,2]

There is no cure for Dravet syndrome[6]

The condition affects **1 in 15,700** to **1 in 40,900** births[7,8]

Dravet syndrome can be misdiagnosed for other epilepsies or go undiagnosed[9]

Diagnosis is based on clinical evaluation and can be confirmed by genetic testing[10]



of children diagnosed with Dravet syndrome carry a mutation to a gene, known as SCN1A[3]

5%-10%

cases are **inherited**[11–15]

90%-95%

cases are completely random[11–15]

4%-20%

mortality rate by adulthood[16,17]

Seizures in Dravet syndrome

- Begin within the first year of life[18]
- Present in a developmentally normal infant[18]
- Can be repetitive[18]
- Can sometimes be prolonged (more than 5 minutes of continuous seizure activity without recovery)[19]
- Seizures are not adequately controlled in **90%** of people with Dravet syndrome[20]

Seizures can be triggered by daily occurrences[21]

Emotional stress or excitement

Sunlight

Flashing lights or patterns

Changes in body temperature

Dravet syndrome involves multiple types of seizures including:[3,22–27]

Generalised tonic-clonic:
Begins with stiffness in the arms and legs, followed by jerky movements in the arms, legs, and head with a loss of consciousness

Myoclonic:
Involuntary, brief, jerk-like movements that cause a sudden muscle contraction

Hemiclonic:
Affects only one side of the body

Tonic:
Stiffness in the arms and legs

Clonic:
Jerky movements in the arms, legs, and head

Tonic-atonic:
Muscles in the body become stiff and then relax

Focal with clearly observable motor signs:
Affects a limited area of the brain and the affected person remains conscious

There are **four stages** of **Dravet syndrome:**

Febrile stage (infancy):[28]
High probability of diagnosis within the first year, characterised by long-lasting seizures related to fever, often requiring emergency treatment

Worsening stage (1-5 years):[28,29]
Motor seizures become more common, triggered by environmental factors. Other seizure types may appear, such as myoclonic seizures or absences. Children may show lack of coordination, loss of muscle tone, and a decline in dexterity

Stabilisation stage (around 10 years):[28,30]
Seizures become shorter, less frequent, occurring during sleep. Tonic seizures may occur, with milder forms having one episode per year. Patients develop a crouching gait, often leaning on others or using a wheelchair. Cognitive impairment is often present

Adulthood:[28,30,31]
Seizures persist, mainly during sleep, with generalised tonic-clonic seizures. Progressive worsening in adulthood includes movement disorders, tremors, and symptoms akin to Parkinson's disease. Other seizure types may diminish, but adults may face additional health problems due to Dravet syndrome. About a quarter of patients may also experience loss of bone density with an increased risk of fractures

SUDEP (sudden unexpected death in epilepsy)

Is a fear for parents and caregivers of people living with Dravet syndrome and the risk should be discussed with a healthcare professional[32,33]

The risk of SUDEP in children living with Dravet syndrome is estimated to be **30 times greater than** other childhood-onset epilepsies[34,35]

Current treatment options

1. Antiseizure medications[36]
2. Ketogenic diet[37,38]
3. Trigger management[36]
4. Vagus nerve stimulation (pacemaker-like device that sends electrical impulses to the vagus nerve in the neck)[39]

Aspects of patients' daily life affected by Dravet syndrome:[40]



Sleep - Sleep difficulties worsen seizures and more seizures lead to less sleep, creating a cycle

Feeding - Individuals tend to experience feeding problems

Gait disturbance - Can impact patient's independence and ability to walk

Toilet training - Patients tend to be late to learn and are sometimes incontinent

School - Individuals require additional support and seizures can cause missed school day

Cognitive problems

Motor and behavioural disorders increasing with age

Impact on family and caregivers

The responsibility of care can have a significant impact on day-to-day life.[4]

The lives of Dravet syndrome patients, and those of their caregivers and families, are directly and indirectly impacted by the physical and emotional demands of the disease[41]

35%

of adult siblings report a history of treatment

66%

of caregivers experience depression due to the for clinical depression[42]

devastating nature of Dravet syndrome[31]

81%

stopped working because of their caregiving responsibilities[4]



58%

of siblings aged 9-12 reported feeling worried or scared when their sibling has a seizure[42]

74%

of caregivers report concerns about the emotional impact on siblings of children with Dravet syndrome[31]

79%

of siblings aged 9-12 feared that their siblings might die[42]

References

1. Campbell JD, Whittington MD, Kim CH, et al. Epilepsy Behav. 2018;80:152–6. **2.** Cardenal-Muñoz E, Auvin S, Villanueva V, et al. Epilepsia Open. 2022;7(1):11–26. **3.** Zuberi SM, Wirrell E, Yozawitz E, et al. Epilepsia. 2022;63(6):1349–97. **4.** Lagae L, Irwin J, Gibson E, et al. Seizure. 2019;65:72– 9. **5.** Wirrell EC, Hood V, Knupp KG, et al. Epilepsia. 2022;63(7):1761–77. **6.** Dravet Syndrome UK. Treatments and Outcomes. https://www.dravet.org.uk/treatments/#:~:text=There%20is%20currently%20no%20cure,on%20controlling%20or%20minimising%20seizures. Accessed October 2024. **7.** Wu YW, Sullivan J, McDaniel SS, et al. Pediatrics. 2015;136(5):e1310–5. **8.** Brunklaus A, Ellis R, Reavey E, et al. Brain. 2012;135(Pt 8):2329–36. **9.** Gil-Nagel A, Sanchez-Carpintero R, San Antonio V, et al. Rev Neurol. 2019;68(2):75–81. **10.** Cetica V, Chiari S, Mei D, et al. Neurology. 2017;88(11):1037–44. **11.** Marini C, Scheffer IE, Nabbout R, et al. Epilepsia. 2011;52(S2):24–9. **12.** Claes L, Del-Favero J, Ceulemans B, et al. Am J Hum Genet. 2001;68(6):1327–32. **13.** Nabbout R, Gennaro E, Dalla Bernardina B, et al. Neurology. 2003;60(12):1961–7. **14.** Wallace RH, Hodgson BL, Grinton BE, et al. Neurology. 2003;61(6):765–9. **15.** Fujiwara T, Sugawara T, Mazaki-Miyazaki E, et al. Brain. 2003;126 (Pt 3):531–46. **16.** Cross JH, Galer BS, Gil-Nagel A, et al. Seizure. 2021;93:154–9. **17.** Sullivan J, Benitez A, Roth J, et al. Epilepsia. 2024;65(5):1240–63. **18.** Dravet C. Epilepsia. 2011;52(S2):3–9. **19.** Wylie T, Sandhu DS, Murr NI. Status Epilepticus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Accessed October 2024. **20.** Lagae L, Brambilla I, Mingorance A, et al. Dev Med Child Neurol. 2018;60(1):63–72. **21.** UCSF Benioff Children's Hospital. Dravet syndrome. www.ucsfbenioffchildrens.org/conditions/dravet_syndrome/treatment.html. Updated Feb 2024. Accessed October 2024. **22.** Wirrell EC, Laux L, Donner E, et al. Pediatr Neurol. 2017;68:18–34.e3. **23.** Epilepsy Society. Seizures An introduction to epileptic seizures. https://epilepsysociety.org.uk/sites/default/files/2023-12/SeizuresNovember2023_3.pdf. Updated Nov 2023. Accessed October 2024. **24.** Edwards JC. CNS Spectr. 2001;6(9):750–5. **25.** Fisher RS, Cross HJ, D'Souza C, et al. Epilepsia. 2017;58(4):531–42. **26.** Johns Hopkins Medicine. Types of Seizures. www.hopkinsmedicine.org/health/conditions-and-diseases/epilepsy/types-of-seizures. Accessed October 2024. **27.** Medlink® Neurology. Hemiclonic seizures. www.medlink.com/articles/hemiclonic-seizures. Accessed October 2024. **28.** Gataullina S, Dulac O. Seizure. 2017;44:58–64. **29.** Miller IO, Sotero de Menezes MA. SCN1A Seizure Disorders. 2007. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. Accessed October 2024. **30.** Wyers L, Van de Walle P, Hoornweg A, et al. Eur J Paediatr Neurol. 2019;23(3):357–67. **31.** Villas N, Meskis MA, Goodliffe S. Epilepsy Behav. 2017;74:81–6. **32.** Jensen MP, Liljenquist KS, Bocell F, et al. Epilepsy Behav. 2017;74:135–43. **33.** Skluzacek JV, Watts KP, Parsy O, et al. Epilepsia. 2011;52(S2):95–101. **34.** Kalume F. Respir Physiol Neurobiol. 2013;189(2):324–8. **35.** Harden C, Tomson T, Gloss D, et al. Neurology. 2017;88(17):1674–80. **36.** Dravet Syndrome Foundation. Diagnosis and Treatment Guidelines. Available at: https://dravetfoundation.org/hcp-resources/diagnosis-and-treatment/#:~:text=Learn%20and%20avoid%20seizure%20triggers,%2C%20patterns%2C%20and%20flickering%20lights. Accessed: October 2024. **37.** Gorria Redondo N, Angulo García ML, Montesclaros Hortigüela Saeta M, et al. An Pediatr (Barc). 2016;84(6):341–3. **38.** García-Peñas JJ. Rev Neurol. 2018;66(S01):S71–5. **39.** González HFJ, Yengo-Kahn A, Englot DJ. Neurosurg Clin N Am. 2019;30(2):219–30. **40.** Dravet Syndrome UK. DSUK Family Guide. www.dravet.org.uk/dsuk-family-guide/. Updated Jan 2024. Accessed October 2024. **41.** Whittington MD, Knupp KG, Vanderveen G, et al. Epilepsy Behav. 2018;80:109–13. **42.** Bailey LD, Schwartz L, DixonSalazar T, et al. Epilepsy Behav. 2020;112:107377.

© UCB Biopharma SRL, 2024. All rights reserved.

Date of preparation: October 2024 | GL-DA-2400580
Intended for healthcare professionals only

Inspired by **patients.**
Driven by **science.**